C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Bernard Escudier,Camillo Porta,Petri Bono,Thomas Powles,Tim Eisen,Cora N. Sternberg,Juergen E. Gschwend,Ugo De Giorgi,Omi Parikh,Robert E. Hawkins,Emmanuel Sevin,Sylvie Negrier,Sadya Khan,Jose Diaz,Suman Redhu,Faisal Mehmud,David Cella +16 more
TL;DR: Pazopanib was superior to sunitinib in HRQoL measures evaluating fatigue, hand/foot soreness, and mouth/throat soreness and safety as key influencing factors.
Journal ArticleDOI
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer,Dmitry Nosov,Timothy Eisen,Igor Bondarenko,Vladimir Lesovoy,Oleg Lipatov,Piotr Tomczak,Oleksiy Lyulko,Anna Alyasova,Mihai Harza,Mikhail Kogan,Boris Alekseev,Cora N. Sternberg,Cezary Szczylik,David Cella,Cristina Ivanescu,Andrew Krivoshik,Andrew Strahs,Brooke Esteves,Anna Berkenblit,Thomas E. Hutson +20 more
TL;DR: Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.
Journal ArticleDOI
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy : the SPARC trial
Cora N. Sternberg,Daniel P. Petrylak,Oliver Sartor,J. Alfred Witjes,Tomasz Demkow,Jean Marc Ferrero,Jean-Christophe Eymard,Silvia Falcon,Fabio Calabrò,Nicholas D. James,Istvan Bodrogi,Peter Harper,Manfred P. Wirth,William R. Berry,Michael E. Petrone,Thomas J. McKearn,Mojtaba Noursalehi,Martine George,Marcel Rozencweig +18 more
TL;DR: Oral satraplatin delayed progression of disease and pain in patients with metastatic CRPC experiencing progression after initial chemotherapy but did not provide a significant OS benefit.
Journal ArticleDOI
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Philipp Nuhn,Johann S. de Bono,Karim Fizazi,Stephen J. Freedland,Stephen J. Freedland,Maurizio Grilli,Philip W. Kantoff,Guru Sonpavde,Cora N. Sternberg,Srinivasan Yegnasubramanian,Emmanuel S. Antonarakis +10 more
TL;DR: The emergence of new drugs for mCRPC has improved treatment options dramatically and the best strategies for patient selection and optimal sequential use to achieve the longest cumulative survival improvement and to prevent early resistance remain unclear.
Journal ArticleDOI
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
Cora N. Sternberg,Iwona Skoneczna,J. Martijn Kerst,Peter Albers,Sophie D. Fosså,Mads Agerbæk,Herlinde Dumez,Maria De Santis,Christine Theodore,M. G. Leahy,John D. Chester,John D. Chester,Antony Verbaeys,Gedske Daugaard,Lori Wood,J. Alfred Witjes,Ronald de Wit,Lionel Geoffrois,Lisa Sengeløv,George N. Thalmann,Danielle Charpentier,Frederic Rolland,Laurent Mignot,Santhanam Sundar,P. Symonds,John Graham,Florence Joly,Sandrine Marreaud,Laurence Collette,Richard Sylvester +29 more
TL;DR: The data did not show a significant improvement in overall survival with immediate versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for patients with muscle-invasive urothelial carcinoma, and it is possible that some subgroups of patients might still benefit from immediate chemotherapy.